Precision medicine company IMBDX is showing strong performance. The news that it will present research results demonstrating the excellent performance of AlphaLiquid100 and AlphaLiquidHRR at the ASCO Genitourinary Cancers Symposium held in San Francisco, USA, appears to be influencing its stock price.
AlphaLiquid100 and AlphaLiquidHRR are liquid biopsy-based next-generation sequencing (NGS) products that diagnose homologous recombination repair (HRR) gene mutations in metastatic prostate cancer patients.
At 10:16 AM on the 11th, IMBDX was trading at 14,010 KRW, up 13.19% from the previous day.
The study was conducted jointly by IMBDX and AstraZeneca from 2021 to 2024, targeting 933 Asian metastatic prostate cancer patients across 11 countries including Korea, Taiwan, Thailand, Vietnam, and Saudi Arabia.
The research team analyzed mutations in a total of 15 HRR genes using the AlphaLiquid100 and AlphaLiquidHRR NGS panels, identifying HRR gene mutations in 31.5% of all patients. High mutation frequencies were observed in the BRCA1/2, CDK12, ATM, and CHEK2 genes. The frequency and distribution of HRR gene mutations showed similar results to internationally validated tissue-based prostate cancer gene data (such as the PROfound study), thereby proving the reliability of the AlphaLiquid products.
When HRR gene mutations are identified in metastatic prostate cancer patients, they become candidates for PARP inhibitor therapy, which is effective in treating prostate cancer. Therefore, accurate detection of these mutations is a key factor in establishing treatment strategies.
Due to the anatomical characteristics of the prostate, obtaining sufficient cancer tissue samples is difficult, limiting the application of conventional tissue-based genetic tests. Chayong Jun, Chief Medical Officer (CMO) of IMBDX, stated, "This proves that liquid biopsy using the AlphaLiquid panel has HRR gene mutation detection performance equivalent to tissue-based tests." He added, "This is significant as it expands the clinical applicability of non-invasive liquid biopsy for metastatic prostate cancer patients."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
